Trial ends in Request Full Access Tell Your Colleague About Jove

Methods Collections > CRISPR-Cas9: A new era of targeted gene editing

Sridhar Bammidi

Affiliation: Indian Institute of Technology

Sridhar Bammidi is an ocular neurobiologist, with interests primarily in understanding the developmental biology of the retina and the CNS. He is currently a post-doctoral fellow at the Molecular Genetics and Therapeutics Laboratory, School of Biological Sciences and Bio-engineering, Indian Institute of Technology, Kanpur, UP, India.  His specialization includes cell survival and therapeutics using intrinsic and alternate therapies viz. stem cells and molecular gene therapy. In gene therapy using AAV-based vector delivery systems, the constant focus is around increasing the specificity of the vectors as well as their survival and expression over an increased period of time. Both the phenomena involve modification of the viral capsid conformations to increase the specificity of the various serotypes and the sequestration of the same from the cellular and systemic immune interactions of the host. In order to achieve this, he has been working with the post-translational modifications of the vector capsid proteins and also developing multiple-tiered vector systems to deliver the gene of interest. His interest and expertise also involve optimizing the routes of vector delivery, in rodent model systems, for maximum effect.  He is trained in ocular and systemic injections, in-vitro assays, rodent model development, AAV based delivery systems, cellular, molecular, and electrophysiological aspects in wild type and transgenic mouse models.

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
simple hit counter